Herbal Based Nano-Drug Delivery System for Various Clinical and Therapeutic Applications: Current Status and Future Prospects

[1]Sakshi Tatpal, [2]Rajkumari Lodhi, [3]Dr.Satish Nayak
[1]Student, [2]Assistant Professor, [3]Principal
[123]Bansal college of pharmacy

Abstract*—Herbal medicines have been used for centuries in the prevention and treatment of numerous diseases due to their therapeutic efficacy, safety, and affordability. However, many phytoconstituents suffer from poor aqueous solubility, low bioavailability, instability, rapid metabolism, and limited target specificity, which restrict their clinical applications. Nanotechnology has emerged as a promising strategy to overcome these limitations through the development of herbal nano-drug delivery systems. Nano formulations such as liposomes, phytosomes, polymeric nanoparticles, solid lipid nanoparticles, Nano emulsions, dendrimers, and nanomicelles enhance the therapeutic performance of herbal compounds by improving their solubility, stability, controlled release, and targeted delivery. Herbal nano-drug delivery systems have demonstrated significant potential in cancer therapy, neurological disorders, cardiovascular diseases, diabetes, infectious diseases, wound healing, and inflammatory conditions. Recent advancements in nanocarrier design have further facilitated site-specific drug delivery and improved patient compliance. Despite these achievements, challenges related to toxicity, regulatory approval, standardization, large-scale manufacturing, and clinical translation remain significant. This review discusses the principles, types, therapeutic applications, current status, challenges, and future prospects of herbal nano-drug delivery systems, highlighting their role in modern healthcare and personalized medicine. Recent evidence indicates that nanocarriers improve the bioavailability, stability, and therapeutic efficacy of phytoconstituents while enabling targeted and controlled drug delivery.

***Index Terms*—Herbal medicine, Nanotechnology, Nano-drug delivery systems, Phytosomes, Liposomes, Nanoparticles, Therapeutic applications, Targeted drug delivery.**

I. Introduction

Medicinal plants have been an integral component of traditional healthcare systems worldwide. According to global estimates, a substantial proportion of the population relies on herbal medicines for primary healthcare needs. Herbal products contain numerous bioactive compounds such as alkaloids, flavonoids, terpenoids, glycosides, polyphenols, and tannins that exhibit diverse pharmacological activities including antioxidant, anti-inflammatory, antimicrobial, anticancer, antidiabetic, and neuroprotective effects.

Despite their therapeutic potential, many phytoconstituents exhibit poor water solubility, low membrane permeability, rapid degradation, and inadequate bioavailability. These limitations significantly reduce their clinical efficacy. Nanotechnology offers innovative solutions by incorporating herbal bioactive compounds into nanoscale delivery systems, thereby enhancing their absorption, stability, bioavailability, and target specificity.

The integration of herbal medicine and nanotechnology has led to the development of herbal nano-drug delivery systems (HNDDS), which represent a rapidly growing area in pharmaceutical research.

II. Concept of Herbal Nano-Drug Delivery Systems

Herbal nano-drug delivery systems refer to Nano sized carriers ranging from 1–1000 nm that encapsulate, adsorb, or conjugate herbal extracts or phytoconstituents to improve their pharmacokinetic and pharmacodynamics properties.

Objectives

- Enhance bioavailability of herbal compounds
- Improve solubility and dissolution rate
- Protect phytoconstituents from degradation
- Achieve targeted drug delivery
- Provide sustained and controlled release
- Reduce toxicity and side effects
- Improve therapeutic efficacy

Nano carriers enable better interaction with biological membranes, enhanced cellular uptake, and prolonged circulation time.

III. Advantages of Herbal Nano-Drug Delivery Systems

Conventional Herbal Formulations	Nano-Herbal Formulations
Poor solubility	Improved solubility
Low bioavailability	Enhanced bioavailability
Rapid degradation	Increased stability
Non-specific distribution	Targeted delivery
Frequent dosing	Sustained release
Variable therapeutic response	Enhanced efficacy

Major benefits include:

- Improved pharmacokinetics
- Enhanced absorption
- Increased therapeutic index

- Reduced dosage frequency
- Better patient compliance
- Site-specific drug delivery

IV. Types of Herbal Nano-Drug Delivery Systems

4.1 Liposomes

Liposomes are nanosized or microsized vesicular carriers composed of one or more phospholipid bilayers surrounding an aqueous compartment. Due to their structural resemblance to biological cell membranes, liposomes have gained considerable importance as versatile drug delivery systems in pharmaceutical, cosmetic, and biomedical applications. They are widely employed for the targeted delivery of therapeutic agents, nucleic acids, proteins, vaccines, and cosmetic ingredients, enhancing their stability, bioavailability, and cellular uptake.

The unique architecture of liposomes is based on amphiphilic lipids, primarily phospholipids and cholesterol, which contain both hydrophilic (water-attracting) head groups and hydrophobic (lipid-attracting) tail regions. When dispersed in an aqueous environment, these molecules spontaneously organize into a bilayer structure in which the hydrophobic tails align inward, shielded from water, while the hydrophilic heads orient toward the surrounding aqueous medium and the internal aqueous core.

One of the most significant advantages of liposomes is their ability to encapsulate a wide range of bioactive compounds with different physicochemical properties. Hydrophilic substances can be entrapped within the aqueous core, whereas hydrophobic or lipophilic compounds can be incorporated into the lipid bilayer membrane. This dual-loading capability makes liposomes highly effective carriers for delivering both water-soluble and lipid-soluble therapeutic agents, thereby improving their pharmacological performance and targeted action.

Herbal Examples

- Curcumin liposomes
- Green tea extract liposomes
- Ginseng liposomes

Liposomes significantly improve membrane permeation and therapeutic availability of herbal extracts.

4.2 Phytosomes

Phytosomes are specialized lipid-based vesicular systems developed to enhance the delivery and bioavailability of herbal bioactive compounds. The technology involves the formation of a molecular complex between phytoconstituents and phospholipids, typically phosphatidylcholine, resulting in improved absorption and therapeutic efficacy. The term "phytosome" combines the words "phyto" (plant) and "some" (cell-like structure), reflecting its role in transporting plant-derived compounds across biological membranes.

Unlike conventional herbal formulations, where active constituents are merely mixed with carriers, phytosomes form stable complexes through chemical interactions between the polar groups of phytochemicals and phospholipid molecules. This unique structure improves the solubility, stability, and membrane permeability of phytoconstituents. The phospholipid component possesses both hydrophilic and lipophilic properties, enabling the phytosome complex to readily cross lipid-rich biological barriers and enhance systemic absorption.

Phytosome technology has been successfully applied to numerous herbal compounds, including curcumin, silymarin, quercetin, Ginkgo biloba flavonoids, and green tea polyphenols. Studies have demonstrated that phytosomes significantly improve the pharmacokinetic profile and therapeutic performance of these phytochemicals compared to conventional extracts. Due to their enhanced bioavailability, reduced degradation, and improved target delivery, phytosomes have become an important nanocarrier system in the development of modern herbal medicines, nutraceuticals, and cosmeceutical products.

Examples

- Curcumin phytosomes
- Silybin phytosomes
- Ginkgo biloba phytosomes

Phytosomes have demonstrated superior pharmacokinetic profiles compared with conventional herbal preparations.

4.3 Polymeric Nanoparticles

Polymeric nanoparticles are colloidal drug delivery systems ranging in size from approximately 10 to 1000 nm, composed of natural or synthetic biodegradable polymers. These nanocarriers have attracted significant attention in pharmaceutical research due to their ability to improve the stability, bioavailability, controlled release, and targeted delivery of therapeutic agents, including herbal bioactive compounds. Polymeric nanoparticles can be designed as nanospheres, in which the drug is uniformly dispersed throughout the polymer matrix, or nanocapsules, where the drug is confined within a polymeric shell surrounding a core.

The polymers used in nanoparticle preparation may be synthetic, such as poly(lactic-co-glycolic acid) (PLGA), polycaprolactone (PCL), and polylactic acid (PLA), or natural, such as chitosan, alginate, gelatin, and dextran. These polymers are biocompatible and biodegradable, making them suitable for biomedical applications. The encapsulation of phytoconstituents within polymeric nanoparticles protects them from chemical degradation, enzymatic metabolism, and premature elimination, thereby enhancing their therapeutic effectiveness.

One of the major advantages of polymeric nanoparticles is their ability to provide sustained and controlled drug release while improving tissue-specific targeting. Surface modification with ligands, antibodies, or polymers can further enhance their ability to deliver drugs to specific cells or organs. Polymeric nanoparticles have been extensively investigated for the delivery of herbal compounds such as curcumin, quercetin, resveratrol, berberine, and catechins. These nanoformulations have demonstrated improved solubility, prolonged circulation time, enhanced cellular uptake, and superior therapeutic outcomes in the treatment of cancer, neurological disorders, cardiovascular diseases, diabetes, and inflammatory conditions. Owing to these benefits, polymeric nanoparticles are considered one of the most promising nanocarrier systems for advanced herbal drug delivery.

4.4 Solid Lipid Nanoparticles (SLNs)

Solid Lipid Nanoparticles (SLNs) are advanced colloidal drug delivery systems composed of biocompatible and biodegradable lipids that remain solid at both room and body temperatures. Typically ranging in size from 50 to 1000 nm, SLNs combine the advantages of conventional lipid-based carriers and polymeric nanoparticles, offering improved drug stability, controlled release, enhanced bioavailability, and reduced toxicity. Due to these favorable characteristics, SLNs have emerged as promising nanocarriers for the delivery of herbal bioactive compounds and pharmaceutical agents.

The structure of SLNs consists of a solid lipid core stabilized by surfactants or emulsifying agents. The lipid matrix can encapsulate lipophilic, hydrophilic, or amphiphilic compounds, protecting them from chemical degradation and environmental stress. Commonly used lipids include triglycerides, fatty acids, waxes, and glyceride mixtures, while surfactants such as polysorbates and lecithin help maintain nanoparticle stability. The solid nature of the lipid matrix enables sustained and controlled drug release, thereby improving therapeutic outcomes.

SLNs offer several advantages, including enhanced drug loading capacity, improved physical stability, prolonged circulation time, targeted drug delivery, and reduced adverse effects. They also facilitate better penetration across biological barriers, making them suitable for oral, topical, ocular, pulmonary, and parenteral administration. Herbal compounds such as curcumin, quercetin, resveratrol, berberine, and catechins have been successfully incorporated into SLNs to overcome issues related to poor solubility and low bioavailability. Consequently, SLNs have demonstrated significant potential in the treatment of cancer, neurological disorders, cardiovascular diseases, inflammatory conditions, and microbial infections. Their safety profile, scalability, and versatility make them one of the most widely investigated nanocarrier systems in modern herbal drug delivery research.

4.5 Nanoemulsions

Nanoemulsions are advanced colloidal dispersion systems consisting of two immiscible liquids, typically oil and water, stabilized by surfactants and co-surfactants, with droplet sizes generally ranging from 20 to 200 nm. Due to their extremely small droplet size, nanoemulsions exhibit high kinetic stability, large surface area, enhanced solubilization capacity, and improved drug absorption. These characteristics make nanoemulsions highly effective carriers for the delivery of herbal bioactive compounds and pharmaceutical agents.

Nanoemulsions can be classified into oil-in-water (O/W), water-in-oil (W/O), and bicontinuous systems depending on the composition and distribution of the dispersed phase. The small droplet size facilitates intimate contact with biological membranes, leading to enhanced permeability, rapid absorption, and increased bioavailability of encapsulated phytoconstituents. Furthermore, nanoemulsions protect sensitive herbal compounds from degradation caused by environmental factors such as oxidation, light, and enzymatic activity.

The major advantages of nanoemulsions include improved solubility of poorly water-soluble compounds, enhanced therapeutic efficacy, controlled drug release, reduced dosing frequency, and better patient compliance. They are suitable for multiple routes of administration, including oral, topical, ocular, nasal, and parenteral delivery. Numerous herbal compounds such as curcumin, essential oils, neem oil, tea tree oil, resveratrol, and various plant polyphenols have been successfully formulated into nanoemulsions to enhance their pharmacological performance. Nanoemulsion-based herbal formulations have demonstrated significant potential in the treatment of cancer, microbial infections, inflammatory disorders, skin diseases, and neurological conditions. Owing to their versatility, ease of preparation, and ability to improve the delivery of phytochemicals, nanoemulsions have become one of the most promising nanocarrier systems in herbal drug delivery research.

Examples

- Neem oil nanoemulsion
- Turmeric nanoemulsion
- Essential oil nanoformulations

V. Therapeutic and Clinical Applications

5.1 Cancer Therapy

Many phytochemicals such as curcumin, resveratrol, quercetin, and epigallocatechin gallate exhibit potent anticancer activity but suffer from poor bioavailability.

Nano formulations:

- Improve tumor targeting
- Reduce systemic toxicity
- Enhance intracellular uptake
- Increase therapeutic efficacy

Applications include breast cancer, lung cancer, colorectal cancer, and prostate cancer treatment.

5.2 Neurological Disorders

Nano-herbal formulations have shown promise in:

1.Alzheimer's Disease

Alzheimer's disease is a progressive neurodegenerative disorder characterized by memory loss, cognitive impairment, and behavioral changes. The presence of the blood-brain barrier (BBB) significantly limits the delivery of therapeutic agents to the brain. Herbal nano-drug delivery systems have emerged as promising approaches for enhancing the brain uptake of phytoconstituents such as curcumin, resveratrol, quercetin, and Bacopa monnieri extracts. Nanoformulations improve the bioavailability, stability, and targeted delivery of these compounds, helping to reduce amyloid-β plaque formation, oxidative stress, neuroinflammation, and neuronal degeneration associated with Alzheimer's disease.

2. Parkinson's Disease

Parkinson's disease is a chronic neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the substantia nigra region of the brain. Herbal bioactive compounds such as curcumin, green tea polyphenols, resveratrol, and ginsenosides possess antioxidant and neuroprotective properties that may help slow disease progression. Encapsulation of these phytochemicals into nanoparticles, liposomes, or nanoemulsions enhances their ability to cross the blood-brain barrier, improves neuronal targeting, and provides sustained therapeutic effects, thereby offering potential benefits in the management of Parkinson's disease.

3. Epilepsy

Epilepsy is a neurological disorder characterized by recurrent and uncontrolled seizures resulting from abnormal electrical activity in the brain. Several herbal compounds, including flavonoids, alkaloids, and terpenoids, have demonstrated anticonvulsant and neuroprotective activities. Nano-based delivery systems improve the solubility, stability, and brain penetration of these phytoconstituents, enabling more effective seizure control and reduced systemic side effects. Herbal nanoformulations also provide controlled drug release, which may contribute to improved therapeutic outcomes in epilepsy management.

4. Neuroinflammation

Neuroinflammation plays a critical role in the development and progression of various neurological disorders, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and traumatic brain injury. Excessive activation of microglial cells and the release of pro-inflammatory cytokines contribute to neuronal damage and cognitive decline. Herbal phytochemicals such as curcumin, quercetin, resveratrol, and catechins possess potent anti-inflammatory and antioxidant properties. Nano-drug delivery systems enhance their bioavailability and facilitate targeted delivery to inflamed brain tissues, resulting in improved suppression of inflammatory pathways and protection against neurodegeneration.

Examples include nano-curcumin, nano-resveratrol, and nano-Bacopa formulations capable of crossing the blood-brain barrier more efficiently.

5.3 Cardiovascular Diseases

Cardiovascular diseases (CVDs) remain one of the leading causes of morbidity and mortality worldwide. Oxidative stress, inflammation, endothelial dysfunction, and lipid abnormalities play crucial roles in the development and progression of cardiovascular disorders. Numerous herbal phytoconstituents possess cardioprotective properties; however, their therapeutic potential is often limited by poor solubility, low bioavailability, and rapid metabolism. Nano-herbal drug delivery systems have emerged as an effective strategy to overcome these limitations and enhance the clinical efficacy of plant-derived bioactive compounds.

Nanoformulations improve the delivery of cardioprotective phytochemicals by increasing their absorption, stability, and targeted distribution to cardiovascular tissues. These systems help reduce oxidative stress by scavenging free radicals, improve endothelial function by enhancing nitric oxide availability, and increase the overall bioavailability of therapeutic compounds. Furthermore, controlled and sustained drug release offered by nanocarriers contributes to prolonged therapeutic action and improved patient outcomes.

Several herbal nanoformulations have demonstrated promising cardioprotective effects. Garlic nanoparticles exhibit antioxidant, antihypertensive, and lipid-lowering activities, helping to reduce the risk of atherosclerosis and cardiovascular complications. Nanoformulations of *Ginkgo biloba* improve vascular circulation, protect endothelial cells from oxidative damage, and enhance blood flow. Similarly, resveratrol-loaded nanoparticles have shown significant potential in preventing cardiac inflammation, reducing oxidative injury, and improving cardiovascular function through enhanced bioavailability and targeted delivery.

The integration of herbal medicines with nanotechnology offers a novel and effective approach for the prevention and management of cardiovascular diseases, providing improved therapeutic efficacy while minimizing adverse effects.

5.5 Diabetes Management

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from impaired insulin secretion, insulin action, or both. Long-term complications of diabetes include cardiovascular diseases, nephropathy, neuropathy, and retinopathy. Several herbal phytoconstituents possess antidiabetic properties; however, their clinical effectiveness is often restricted by poor aqueous solubility, low gastrointestinal absorption, and rapid metabolic degradation. Nano-herbal drug delivery systems have been developed to address these challenges and enhance the therapeutic potential of herbal antidiabetic agents.

5.4 Diabetes Management

Nano-herbal drug delivery systems have shown considerable promise in the management of diabetes mellitus by enhancing the therapeutic efficacy of plant-derived bioactive compounds. Many phytoconstituents with antidiabetic activity suffer from poor water solubility, limited gastrointestinal absorption, rapid metabolism, and low bioavailability. Nanoformulations overcome these challenges by improving drug stability, enhancing intestinal absorption, facilitating controlled release, and increasing the bioavailability of herbal compounds.

These advanced delivery systems contribute to better glycemic control by improving glucose metabolism, enhancing insulin sensitivity, reducing oxidative stress, and protecting pancreatic β-cells from damage. Furthermore, nano-herbal formulations can provide sustained therapeutic effects, reduce dosing frequency, and minimize adverse effects associated with conventional antidiabetic therapies.

Several herbal compounds have been successfully incorporated into nanocarrier systems for diabetes management. **Berberine nanoparticles** have demonstrated improved absorption and enhanced hypoglycemic activity, leading to better regulation of blood glucose levels and insulin resistance. **Curcumin nanoparticles** exhibit potent antioxidant and anti-inflammatory effects, helping to reduce diabetic complications while improving insulin sensitivity and pancreatic function. Similarly, **cinnamon nanoformulations** have shown potential in enhancing glucose uptake, improving insulin signaling pathways, and supporting overall glycemic control.

The application of nanotechnology in herbal antidiabetic therapy offers a promising approach for improving treatment outcomes and reducing the long-term complications associated with diabetes mellitus.

Benefits include improved pharmacokinetics and reduced dosing requirements.

5.5 Antimicrobial Applications

Nano-herbal systems exhibit potent activity against bacterial, fungal, and viral pathogens.

Examples:

- Neem nanoparticles
- Tea tree oil nanoemulsions
- Garlic nanoparticles

These systems improve penetration and sustained antimicrobial action.

5.6 Wound Healing and Dermatology

Nano-herbal formulations accelerate wound healing through:

- Enhanced skin penetration
- Controlled release
- Antioxidant activity
- Antimicrobial protection

Examples:

- Aloe vera nanoparticles
- Curcumin nanogels
- Centella asiatica nanoformulations

VI. Current Status of Herbal Nanoformulations

Recent years have witnessed substantial growth in nano-herbal research. Several phytosome and liposomal formulations have entered commercial markets and clinical evaluation stages. Research has focused on improving pharmacokinetics, targeted delivery, and therapeutic effectiveness. Nanotechnology-based herbal products are increasingly being investigated for oncology, ocular diseases, inflammatory disorders, and metabolic syndromes.

However, only a limited number of nano-herbal products have achieved widespread clinical adoption due to challenges in standardization and regulatory approval.

VII. Challenges and Limitations of Herbal-Based Nanodrug Delivery Systems

Although herbal-based nanodrug delivery systems have demonstrated significant potential in improving the therapeutic efficacy, bioavailability, and targeted delivery of phytoconstituents, several challenges and limitations continue to hinder their widespread clinical application and commercialization. These obstacles encompass technical, safety, regulatory, and economic aspects that must be addressed to ensure the successful translation of nano-herbal formulations from laboratory research to clinical practice.

1. Technical Challenges

One of the major concerns associated with nano-herbal drug delivery systems is the lack of reproducibility during formulation development. Variations in particle size, encapsulation efficiency, drug loading capacity, and release kinetics can occur due to differences in preparation methods and raw material characteristics. Since herbal extracts contain complex mixtures of bioactive compounds, maintaining batch-to-batch consistency becomes particularly challenging.

Another limitation is the stability of nanoformulations. Nanoparticles are prone to aggregation, sedimentation, oxidation, and degradation during storage, which can adversely affect their physicochemical properties and therapeutic performance. Environmental factors such as temperature, pH, humidity, and light exposure further influence formulation stability.

Scale-up and industrial manufacturing also present significant challenges. Techniques that are successful at the laboratory scale often face difficulties when translated to large-scale production due to issues related to process control, equipment requirements, and maintenance of product quality. Achieving uniformity and reproducibility during mass production remains a critical hurdle for the pharmaceutical industry.

2. Safety Concerns

Despite the advantages offered by nanotechnology, concerns regarding the safety and toxicity of nanocarriers remain a major limitation. The small size and high surface area of nanoparticles may result in unexpected biological interactions, leading to cellular toxicity, oxidative stress, inflammation, or tissue damage.

Long-term accumulation of nanoparticles in organs such as the liver, spleen, lungs, and kidneys is another concern. Certain nanomaterials may not be completely eliminated from the body, raising the possibility of chronic toxicity following prolonged administration.

Additionally, some nanocarriers may induce immunogenic or hypersensitivity reactions. The interaction of nanoparticles with the immune system can trigger immune responses, potentially affecting therapeutic efficacy and patient safety. Comprehensive toxicological studies are therefore necessary before clinical approval of herbal nanoformulations.

3. Regulatory Challenges

The regulatory framework governing nano-herbal medicines remains insufficiently developed in many countries. There is currently a lack of standardized guidelines for the characterization, evaluation, manufacturing, and quality assurance of nanomedicines containing herbal ingredients.

Quality control presents another significant challenge due to the complex composition of plant extracts and the sophisticated nature of nanocarriers. Standardization of raw materials, formulation procedures, and analytical methods is essential to ensure consistency, safety, and efficacy.

Furthermore, the approval process for nano-herbal products is often complex and time-consuming. Regulatory authorities require extensive data on pharmacokinetics, biodistribution, toxicity, stability, and clinical efficacy, which increases the duration and cost of product development.

4. Economic Constraints

The high cost of production represents a major barrier to the commercialization of herbal nanomedicines. The synthesis of nanoparticles often requires specialized equipment, advanced technologies, skilled personnel, and stringent quality control measures, all of which contribute to increased manufacturing expenses.

Research and development costs are also substantial due to the need for extensive preclinical and clinical studies. Small pharmaceutical companies and research institutions may face financial limitations in advancing nano-herbal formulations through the regulatory pathway.

Moreover, the high production costs may result in expensive final products, potentially limiting accessibility and affordability, particularly in developing countries where herbal medicines are widely used as cost-effective healthcare alternatives.

VIII. Future Prospects of Herbal Nano-Drug Delivery Systems

The integration of nanotechnology with herbal medicine has opened new avenues for the development of advanced therapeutic systems. Although considerable progress has been achieved in recent years, future research is expected to focus on improving the efficacy, safety, precision, and commercial viability of herbal nano-drug delivery systems. Emerging technologies such as artificial intelligence, personalized medicine, smart nanocarriers, and green nanotechnology are anticipated to revolutionize the field and accelerate the clinical translation of nano-herbal therapeutics.

8.1 Personalized Nanoherbal Medicine

The future of healthcare is moving toward personalized or precision medicine, where treatments are tailored according to an individual's genetic makeup, physiological characteristics, and disease profile. Herbal nanoformulations can be customized to meet specific patient requirements, thereby maximizing therapeutic efficacy while minimizing adverse effects. Advances in genomics, proteomics, and pharmacogenomics will enable the identification of biomarkers that can guide the selection of appropriate phytoconstituents and nanocarriers. Such personalized nanoherbal therapies may prove particularly beneficial in the management of complex diseases such as cancer, diabetes, cardiovascular disorders, and neurodegenerative diseases.

8.2 Development of Smart Nanocarriers

Smart or stimuli-responsive nanocarriers represent one of the most promising advancements in nano-drug delivery. These systems are designed to release therapeutic agents only in response to specific physiological or pathological triggers such as pH changes, temperature variations, enzyme activity, magnetic fields, or light exposure. In herbal medicine, smart nanocarriers can facilitate controlled and site-specific release of bioactive compounds, reducing systemic toxicity and improving treatment outcomes. For example, pH-sensitive nanoparticles can selectively release anticancer phytochemicals within the acidic tumor microenvironment while minimizing effects on healthy tissues.

8.3 Artificial Intelligence-Assisted Formulation Design

Artificial intelligence (AI) and machine learning technologies are increasingly being utilized in pharmaceutical research and development. AI-driven computational models can analyze large datasets and predict optimal nanoparticle characteristics, including particle size, drug-loading efficiency, release kinetics, stability, and biological interactions. These technologies can significantly reduce formulation development time and costs while improving product quality and therapeutic performance. Furthermore, AI can assist in identifying novel phytoconstituents, predicting their pharmacological activities, and optimizing nanoformulation strategies for various diseases.

8.4 Advanced Targeted Drug Delivery Systems

Future nano-herbal formulations are expected to incorporate sophisticated targeting mechanisms that enhance the selective delivery of therapeutic agents to diseased tissues. Ligand-mediated targeting, antibody-conjugated nanoparticles, peptide-based targeting systems, and receptor-specific nanocarriers can improve drug accumulation at the desired site while minimizing off-target effects. Such targeted delivery approaches hold great promise for the treatment of cancer, Alzheimer's disease, Parkinson's disease, cardiovascular disorders, and other chronic illnesses. Enhanced targeting efficiency may also allow lower therapeutic doses, thereby reducing toxicity and improving patient compliance.

8.5 Green Nanotechnology and Sustainable Manufacturing

Growing environmental concerns have encouraged the development of eco-friendly approaches for nanoparticle synthesis. Green nanotechnology utilizes plant extracts, microorganisms, and naturally derived materials for the production of nanoparticles, eliminating the need for hazardous chemicals and energy-intensive processes. Plant-mediated synthesis of nanoparticles offers advantages such as biocompatibility, cost-effectiveness, sustainability, and reduced environmental impact. Future research is likely to focus on optimizing green synthesis methods and scaling them for industrial production, thereby supporting sustainable pharmaceutical development.

8.6 Clinical Translation and Commercialization

Despite promising preclinical findings, relatively few herbal nanoformulations have successfully reached the market. Future efforts will focus on conducting large-scale clinical trials to establish the safety, efficacy, pharmacokinetics, and long-term therapeutic benefits of nano-herbal medicines. Additionally, the development of standardized manufacturing protocols and harmonized international regulatory guidelines will facilitate product approval and commercialization. Collaboration among researchers, pharmaceutical industries, healthcare professionals, and regulatory agencies will be essential for translating laboratory innovations into clinically approved therapies.

8.7 Integration with Emerging Biomedical Technologies

The convergence of herbal nanomedicine with other advanced technologies such as biotechnology, gene therapy, biosensors, and regenerative medicine may create next-generation therapeutic platforms. Multifunctional nanoparticles capable of simultaneous diagnosis, monitoring, and treatment (theranostics) are expected to play an increasingly important role in personalized healthcare. Such integrated systems may significantly improve disease management and therapeutic outcomes in the coming decades.

IX. Conclusion

Herbal nano-drug delivery systems represent a revolutionary advancement in pharmaceutical sciences by combining the therapeutic benefits of medicinal plants with modern nanotechnology. These systems effectively overcome major limitations of conventional herbal formulations, including poor solubility, instability, and low bioavailability. Various nanocarriers such as liposomes, phytosomes, polymeric nanoparticles, solid lipid nanoparticles, and nanoemulsions have demonstrated remarkable potential in enhancing the efficacy of phytoconstituents across a broad range of therapeutic applications, including cancer, neurological disorders, cardiovascular diseases, diabetes, infectious diseases, and wound healing. Although challenges related to safety, regulatory approval, standardization, and commercialization remain, ongoing research and technological innovations are expected to accelerate clinical translation. The future integration of nanotechnology, artificial intelligence, and personalized medicine will further strengthen the role of herbal nano-drug delivery systems in next-generation healthcare.

References

[1] Torchilin, V.P. (2005). Recent advances with liposomes as pharmaceutical carriers. *Nature Reviews Drug Discovery*, 4(2), 145–160.

[2] Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., et al. (2013). Liposome: Classification, preparation, and applications. *Nanoscale Research Letters*, 8, 102.

[3] Pattni, B.S., Chupin, V.V., & Torchilin, V.P. (2015). New developments in liposomal drug delivery. *Chemical Reviews*, 115(19), 10938–10966.

[4] Bozzuto, G., & Molinari, A. (2015). Liposomes as nanomedical devices. *International Journal of Nanomedicine*, 10, 975–999.

[5] Kidd, P.M., & Head, K. (2005). A review of the bioavailability and clinical efficacy of milk thistle phytosome: A silybin-phosphatidylcholine complex. *Alternative Medicine Review*, 10(3), 193–203.

[6] Semalty, A., Semalty, M., Rawat, B.S.M., & Franceschi, F. (2010). Supramolecular phospholipids-polyphenolics interactions: The phytosome strategy to improve the bioavailability of phytochemicals. *Fitoterapia*, 81(5), 306–314.

[7] Lu, M., Qiu, Q., Luo, X., et al. (2019). Phyto-phospholipid complexes (phytosomes): A novel strategy to improve the bioavailability of active constituents. *Asian Journal of Pharmaceutical Sciences*, 14(3), 265–274.

[8] Bombardelli, E., Curri, S.B., Della Loggia, R., Del Negro, P., Gariboldi, P., & Tubaro, A. (1989). Complexes between phospholipids and vegetal derivatives of biological interest. *Fitoterapia*, 60, 1–9.

[9] Kumari, A., Yadav, S.K., & Yadav, S.C. (2010). Biodegradable polymeric nanoparticles based drug delivery systems. *Colloids and Surfaces B: Biointerfaces*, 75(1), 1–18.

[10] Mohanraj, V.J., & Chen, Y. (2006). Nanoparticles: A review. *Tropical Journal of Pharmaceutical Research*, 5(1), 561–573.

[11] Danaei, M., Dehghankhold, M., Ataei, S., et al. (2018). Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. *Pharmaceutics*, 10(2), 57.

[12] Anselmo, A.C., & Mitragotri, S. (2019). Nanoparticles in the clinic: An update. *Bioengineering & Translational Medicine*, 4(3), e10143.

[13] Mukherjee, S., Ray, S., & Thakur, R.S. (2009). Solid lipid nanoparticles: A modern formulation approach in drug delivery system. *Indian Journal of Pharmaceutical Sciences*, 71(4), 349–358.

[14] Müller, R.H., Mäder, K., & Gohla, S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery – A review of the state of the art. *European Journal of Pharmaceutics and Biopharmaceutics*, 50(1), 161–177.

[15] Mukherjee, S., Ray, S., & Thakur, R.S. (2009). Solid lipid nanoparticles: A modern formulation approach in drug delivery system. *Indian Journal of Pharmaceutical Sciences*, 71(4), 349–358.

[16] Mehnert, W., & Mäder, K. (2001). Solid lipid nanoparticles: Production, characterization and applications. *Advanced Drug Delivery Reviews*, 47(2–3), 165–196.

[17] Shah, R., Eldridge, D., Palombo, E., & Harding, I. (2014). Lipid Nanoparticles: Production, Characterization and Stability. Springer, New York.

[18] Pardeike, J., Hommoss, A., & Müller, R.H. (2009). Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. *International Journal of Pharmaceutics*, 366(1–2), 170–184.

[19] Gupta, A., Eral, H.B., Hatton, T.A., & Doyle, P.S. (2016). Nanoemulsions: Formation, properties and applications. *Soft Matter*, 12(11), 2826–2841.

[20] McClements, D.J., & Rao, J. (2011). Food-grade nanoemulsions: Formulation, fabrication, properties, performance, biological fate, and potential toxicity. *Critical Reviews in Food Science and Nutrition*, 51(4), 285–330.

[21] Shakeel, F., Baboota, S., Ahuja, A., Ali, J., Aqil, M., & Shafiq, S. (2008). Nanoemulsions as vehicles for transdermal delivery of aceclofenac. *AAPS PharmSciTech*, 8(4), E104.

[22] Solans, C., Izquierdo, P., Nolla, J., Azemar, N., & Garcia-Celma, M.J. (2005). Nano-emulsions. *Current Opinion in Colloid & Interface Science*, 10(3–4), 102–110.

[23] Ghosh, V., Mukherjee, A., & Chandrasekaran, N. (2013). Eugenol-loaded antimicrobial nanoemulsion preserves fruit juice against microbial spoilage. *Colloids and Surfaces B: Biointerfaces*, 114, 392–397.

[24] Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016). Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. *Journal of Controlled Release*, 235, 34–47.

[25] Karthivashan, G., Ganesan, P., Park, S.Y., Kim, J.S., Choi, D.K. (2018). Therapeutic strategies and nano-drug delivery applications in the treatment of Alzheimer's disease. *Drug Delivery*, 25(1), 307–320.

[26] Teleanu, D.M., Chircov, C., Grumezescu, A.M., & Teleanu, R.I. (2019). Neurotoxicity of nanomaterials and nanoparticles: An overview. *Nanomaterials*, 9(1), 96.

[27] Singh, N.A., Mandal, A.K.A., & Khan, Z.A. (2021). Potential neuroprotective properties of herbal medicines and nanotechnology-based approaches in neurological disorders. *Frontiers in Aging Neuroscience*, 13, 768055.

[28] Bhattamisra, S.K., Yap, K.H., Rao, V., & Choudhury, H. (2020). Multiple biological effects of an oil-rich fraction from medicinal plants against neurodegenerative disorders. *Biomedicine & Pharmacotherapy*, 128, 110303.

[29] Alhakamy, N.A., Fahmy, U.A., Ahmed, O.A.A., et al. (2021). Nanotechnology-based approaches for cardiovascular disease treatment and prevention. *Pharmaceutics*, 13(4), 567.

[30] Salehi, B., Mishra, A.P., Nigam, M., et al. (2019). Resveratrol: A double-edged sword in health benefits. *Biomedicines*, 6(3), 91.

[31] Mahdavi-Roshan, M., Salari, A., Ghorbani, Z., & Ashouri, A. (2020). The role of herbal medicines and nanoformulations in cardiovascular disease management. *Phytotherapy Research*, 34(10), 2505–2523.

[32] Gupta, R., & Sharma, A.K. (2019). Nano-herbal formulations: Emerging strategies for diabetes and cardiovascular disorders. *Journal of Drug Delivery Science and Technology*, 52, 110–122.

[33] Kooti, W., Farokhipour, M., Asadzadeh, Z., Ashtary-Larky, D., & Asadi-Samani, M. (2016). The role of medicinal plants in the treatment of diabetes: A systematic review. *Electronic Physician*, 8(1), 1832–1842.

[34] Pang, B., Zhao, L.H., Zhou, Q., Zhao, T.Y., Wang, H., Gu, C.J., & Tong, X.L. (2015). Application of berberine on treating type 2 diabetes mellitus. *International Journal of Endocrinology*, 2015, 905749.

[35] Rahimi, H.R., Mohammadpour, A.H., Dastani, M., et al. (2016). The effect of nano-curcumin on diabetes and its complications: A review. *Phytotherapy Research*, 30(6), 871–881.

[36] Ranasinghe, P., Pigera, S., Premakumara, G.A.S., Galappaththy, P., Constantine, G.R., & Katulanda, P. (2013). Medicinal properties of cinnamon (*Cinnamomum zeylanicum*): A review. *BMC Complementary and Alternative Medicine*, 13, 275.

[37] Choudhury, H., Gorain, B., Pandey, M., et al. (2019). Recent advances in nanotechnology-based drug delivery systems for diabetes management. *Journal of Drug Delivery Science and Technology*, 53, 101152.

[38] Kesharwani, P., Iyer, A.K., & Jain, N.K. (2015). Nanoformulations for diabetes treatment and management. *Nanomedicine*, 10(9), 1445–1465.

[39] Patravale, V.B., Date, A.A., & Kulkarni, R.M. (2004). Nanosuspensions: A promising drug delivery strategy. *Journal of Pharmacy and Pharmacology*, 56(7), 827–840.

[40] Mukherjee, S., Ray, S., & Thakur, R.S. (2009). Solid lipid nanoparticles: A modern formulation approach in drug delivery system. *Indian Journal of Pharmaceutical Sciences*, 71(4), 349–358.

[41] Ahmad, N., Ahmad, R., Alam, M.A., et al. (2020). Nanotechnology-based herbal medicines: Current status and future prospects. *Current Drug Discovery Technologies*, 17(3), 1–15.

[42] Singh, R.P., Gangadharappa, H.V., & Mruthunjaya, K. (2017). Phytosome: A novel drug delivery system for herbal medicine. *Journal of Drug Delivery Science and Technology*, 38, 163–168.

[43] Ventola, C.L. (2017). Progress in nanomedicine: Approved and investigational nanodrugs. *Pharmacy and Therapeutics*, 42(12), 742–755.

[44] Khan, I., Saeed, K., & Khan, I. (2019). Nanoparticles: Properties, applications and toxicities. *Arabian Journal of Chemistry*, 12(7), 908–931.

[45] Kumari, A., Yadav, S.K., & Yadav, S.C. (2010). Biodegradable polymeric nanoparticles-based drug delivery systems. *Colloids and Surfaces B: Biointerfaces*, 75(1), 1–18.

[46] Rai, M., Pandit, R., Gaikwad, S., & Kövics, G. (2016). Pharmaceutical nanotechnology for enhanced delivery of phytomedicines. *Medicinal Plants and Nanotechnology*, 117–170.

[47] Patravale, V.B., Date, A.A., & Kulkarni, R.M. (2004). Nanosuspensions: A promising drug delivery strategy. *Journal of Pharmacy and Pharmacology*, 56(7), 827–840.

[48] Rai, M., Ingle, A.P., Gupta, I., & Brandelli, A. (2015). Bioactivity of noble metal nanoparticles decorated with biologically active molecules and their application in drug delivery. *International Journal of Pharmaceutics*, 496(2), 159–172.

[49] Ventola, C.L. (2017). Progress in nanomedicine: Approved and investigational nanodrugs. *Pharmacy and Therapeutics*, 42(12), 742–755.

[50] Khan, I., Saeed, K., & Khan, I. (2019). Nanoparticles: Properties, applications and toxicities. *Arabian Journal of Chemistry*, 12(7), 908–931.

[51] Ahmad, N., Ahmad, R., Alam, M.A., et al. (2020). Nanotechnology-based herbal medicines: Current status and future prospects. *Current Drug Discovery Technologies*, 17(3), 1–15.

[52] Bose, S., & Sarkar, N. (2018). Artificial intelligence in pharmaceutical formulation development and drug delivery systems. *Advanced Drug Delivery Reviews*, 131, 1–15.

[53] Singh, R.P., Gangadharappa, H.V., & Mruthunjaya, K. (2017). Phytosome: A novel drug delivery system for herbal medicine. *Journal of Drug Delivery Science and Technology*, 38, 163–168.

[54] Khatami, M., Alijani, H.Q., Fakheri, B.A., et al. (2018). Green synthesis of metal nanoparticles using plants. *IET Nanobiotechnology*, 12(6), 709–723.

[55] Torchilin, V.P. (2014). Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. *Nature Reviews Drug Discovery*, 13(11), 813–827.

[56] Anselmo, A.C., & Mitragotri, S. (2019). Nanoparticles in the clinic: An update. *Bioengineering & Translational Medicine*, 4(3), e10143.